Stock Research for CORT

CORT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CORT Stock Chart & Research Data

The CORT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CORT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CORT Due diligence Resources & Stock Charts

The CORT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CORT Detailed Price Forecast - CNN Money CNN View CORT Detailed Summary - Google Finance
Yahoo View CORT Detailed Summary - Yahoo! Finance Zacks View CORT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CORT Trends & Analysis - Trade-Ideas Barrons View CORT Major Holders - Barrons
NASDAQ View CORT Call Transcripts - NASDAQ Seeking View CORT Breaking News & Analysis - Seeking Alpha
Spotlight View CORT Annual Report - CompanySpotlight.com OTC Report View CORT OTC Short Report - OTCShortReport.com
TradeKing View CORT Fundamentals - TradeKing Charts View CORT SEC Filings - Bar Chart
WSJ View Historical Prices for CORT - The WSJ Morningstar View Performance/Total Return for CORT - Morningstar
MarketWatch View the Analyst Estimates for CORT - MarketWatch CNBC View the Earnings History for CORT - CNBC
StockMarketWatch View the CORT Earnings - StockMarketWatch MacroAxis View CORT Buy or Sell Recommendations - MacroAxis
Bullish View the CORT Bullish Patterns - American Bulls Short Pains View CORT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CORT Stock Mentions - StockTwits PennyStocks View CORT Stock Mentions - PennyStockTweets
Twitter View CORT Stock Mentions - Twitter Invest Hub View CORT Investment Forum News - Investor Hub
Yahoo View CORT Stock Mentions - Yahoo! Message Board Seeking Alpha View CORT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CORT - SECform4.com Insider Cow View Insider Transactions for CORT - Insider Cow
CNBC View CORT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CORT - OTC Markets
Yahoo View Insider Transactions for CORT - Yahoo! Finance NASDAQ View Institutional Holdings for CORT - NASDAQ


Stock Charts

FinViz View CORT Stock Insight & Charts - FinViz.com StockCharts View CORT Investment Charts - StockCharts.com
BarChart View CORT Stock Overview & Charts - BarChart Trading View View CORT User Generated Charts - Trading View




Latest Financial News for CORT


Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Posted on Tuesday April 23, 2024

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.


Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Posted on Monday April 22, 2024

MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etio


Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Posted on Wednesday April 17, 2024

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).


Corcept (CORT) Completes Enrollment in Phase II ALS Study
Posted on Tuesday April 16, 2024

The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.